Financials data is unavailable for this security.
View more
Year on year Alliance Pharma PLC 's net income fell -87.21% from 7.32m to 936.00k despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 32.94% to 39.26%.
| Gross margin | 57.58% |
|---|---|
| Net profit margin | -4.15% |
| Operating margin | 3.64% |
| Return on assets | -1.33% |
|---|---|
| Return on equity | -2.46% |
| Return on investment | -1.47% |
More ▼
Cash flow in GBPView more
In 2022, Alliance Pharma PLC increased its cash reserves by 9.13%, or 2.65m. The company earned 20.97m from its operations for a Cash Flow Margin of 12.53%. In addition the company used 17.03m on investing activities and also paid 876.00k in financing cash flows.
| Cash flow per share | 0.0058 |
|---|---|
| Price/Cash flow per share | 60.30 |
| Book value per share | 0.5127 |
|---|---|
| Tangible book value per share | -0.2455 |
More ▼
Balance sheet in GBPView more
| Current ratio | 1.93 |
|---|---|
| Quick ratio | 1.38 |
| Total debt/total equity | 0.4493 |
|---|---|
| Total debt/total capital | 0.31 |
More ▼
Growth rates in GBP
Year on year, growth in dividends per share increased 5.03% while earnings per share excluding extraordinary items fell by -87.26%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 1.91% |
|---|---|
| Div growth rate (5 year) | 5.94% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -50.88 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -158.89 |
More ▼
